AbbVie Announces Positive Pivotal Phase 3 Data On Elagolix




19.10.16 15:28
dpa-AFX


WASHINGTON (dpa-AFX) - AbbVie (ABBV), a global biopharmaceutical company in cooperation with Neurocrine Biosciences Inc.

(NBIX), announced detailed results from two replicate pivotal Phase 3 clinical trials evaluating the efficacy and safety of Elagolix in premenopausal women who suffer from endometriosis.


The data demonstrate that, compared to placebo at month three and month six, patients treated with Elagolix reported statistically significant reductions in scores for menstrual pain (dysmenorrhea, DYS) and non-menstrual pelvic pain (NMPP) associated with endometriosis as measured by the Daily Assessment of Endometriosis Pain scale.


In the two studies, both doses of Elagolix administered orally demonstrated a statistically significant (p ? 0.001) improvement versus placebo in the percentage of DYS and NMPP responders. In the first study, at month three, 46 percent of patients treated with 150 mg once daily and 76 percent of patients treated with 200 mg twice daily of Elagolix were classified as DYS responders, versus 20 percent of patients in the placebo group. Fifty percent of patients treated with 150 mg once daily and 55 percent of patients treated with 200 mg twice daily of Elagolix were classified as NMPP responders, versus 36 percent of patients in the placebo group. The second pivotal Phase 3 study demonstrated similar results.


At ASRM, AbbVie will present multiple abstracts highlighting primary and secondary efficacy and safety endpoint data from the Phase 3 studies as well as research on the economic burden of endometriosis and endometriosis-related surgery in women in the United States. AbbVie plans to submit a New Drug Application to the U.S. Food and Drug Administration (FDA) for endometriosis in 2017.


Copyright RTT News/dpa-AFX



MMMM





 
 
hier klicken zur Chartansicht

Aktuelle Kursinformationen mehr >
Kurs Vortag Veränderung Datum/Zeit
42,94 $ 45,03 $ -2,09 $ -4,64% 07.12./22:55
 
ISIN WKN Jahreshoch Jahrestief
US64125C1099 900964 57,82 $ 31,25 $
Handelsplatz Letzter Veränderung  Zeit
 
Tradegate (RT)
39,345 € -2,47%  17:04
Frankfurt 41,808 € +3,66%  08:01
Berlin 41,785 € +3,54%  08:08
München 41,805 € +2,88%  08:03
Stuttgart 39,369 € -3,19%  21:41
Nasdaq 42,94 $ -4,64%  22:00
  = Realtime
Aktien des Tages
  


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "GeVestor täglich" unseres Partners GeVestor zu.


Mit der Anmeldung für den Newsletter "Aktien des Tages" stimme ich dem gleichzeitigen Erhalt des "Investors Daily" unseres Partners FID Verlag zu.

Meistgelesene Artikel
Aktuelle Diskussionen
Antw. Thema Zeit
2 NEUROCRINE Biosciences Com. 07.01.14
5 Löschung 19.12.07
3 Löschung 18.01.07
RSS Feeds




Bitte warten...